Trial Profile
Early Phase II Clinical Study of TS-142 in Patients with Insomnia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Vornorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 01 Jul 2022 Primary endpoint has been met. (LS mean difference of WASO from placebo [ Time Frame: Day 1 ]), as per Results published in the Psychopharmacology
- 01 Jul 2022 Primary endpoint has been met. (LS mean difference of LPS from placebo [ Time Frame: Day 1 ]),as per Results published in the Psychopharmacology
- 01 Jul 2022 Results published in the Psychopharmacology